Pegcetacoplan is more effective in treating paroxysmal nocturnal hemoglobinuria compared to Soliris.
hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)
Posted inAutoimmune Diseases, Mergers & Acquisitions, Rare/Orphan Diseases
AstraZeneca + Alexion = Rescue of Both Companies
Alexion Pharmaceuticals, which owns Soliris, one of the most expensive drugs on Earth, has agreed to sell AstraZeneca for $39 billion.